NIVO-LD

Posted by •

Updated: 31 March 2026

Study typeRandomised placebo controlled study
SummaryThe NIVO-LD study is looking at the effect of a single low dose of nivolumab (a drug designed to boost immune responses) on the latent HIV reservoir and HIV immune responses in a closely monitored treatment interruption. There are strict criteria to restart HIV treatment.
Inclusion Criteria
  • HIV+
  • Adults 18–65 years
  • On HIV treatment for > 2 years
  • Undetectable viral load > 2 years
  • CD4 > 500
  • Weight >50kg
Participation requirementsParticipants will receive a single intravenous infusion of nivolumab or placebo followed by an interruption of regular HIV treatment.
StatusCurrently recruiting

Study contact

Contact: Alfred Clinical Research Unit on 03 9076 6908 or clinresearch@alfred.org.au

HIV Cure Community Partnership

Hivcure.com.au is the flagship project of the Australian HIV Cure Community Partnership to promote engagement between HIV cure researchers and people living with HIV. Members include NAPWHA, The Doherty Institute for Infection and Immunity, The Kirby Institute, The Alfred Hospital, Living Positive Victoria and Positive Women Victoria.

Must Read

Scroll to Top